Metabolomics analysis of blood identifies potential biomarkers and possible treatment targets for nocturia.
aged men
metabolomics analysis
nocturia
Journal
Therapeutic advances in urology
ISSN: 1756-2872
Titre abrégé: Ther Adv Urol
Pays: England
ID NLM: 101487328
Informations de publication
Date de publication:
Historique:
received:
16
01
2019
accepted:
20
04
2019
entrez:
18
6
2019
pubmed:
18
6
2019
medline:
18
6
2019
Statut:
epublish
Résumé
Our aim was to investigate the association between serum metabolites and nocturia. A total of 66 males aged 65-80 years were enrolled in this study and stratified according to micturition behavior, which was characterized in terms of the 24 h frequency volume chart (FVC) for 3 consecutive days, the International Prostate Symptom Score (IPSS), and quality-of-life score. The nocturia group included participants with any total IPSS and ⩾1.5 micturitions/night as the mean of 3 nights, while the control group included participants with total IPSS < 8 and <1.5 micturitions/night. We conducted a comprehensive capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) study of plasma metabolites. Between-group comparisons of metabolite levels employed the Welch Of 66 participants, 45 were included in the nocturia group and 21 in the control group. There were no differences in background factors between the two groups. FVC analysis revealed that urine production during night-time, as well as micturition frequency during daytime and night-time were significantly higher in the nocturia group. CE-TOFMS identified eight metabolites whose plasma levels differed between the two groups. Multivariate analysis indicated that increased levels of lauric acid and imidazolelactic acid, as well as decreased levels of thiaproline and glycerol, contribute to the etiology of nocturia in aged men. Our findings suggest that abnormal serum levels of metabolites in several pathways play a role in the pathogenesis of nocturia in aged men.
Sections du résumé
BACKGROUND
BACKGROUND
Our aim was to investigate the association between serum metabolites and nocturia.
METHODS
METHODS
A total of 66 males aged 65-80 years were enrolled in this study and stratified according to micturition behavior, which was characterized in terms of the 24 h frequency volume chart (FVC) for 3 consecutive days, the International Prostate Symptom Score (IPSS), and quality-of-life score. The nocturia group included participants with any total IPSS and ⩾1.5 micturitions/night as the mean of 3 nights, while the control group included participants with total IPSS < 8 and <1.5 micturitions/night. We conducted a comprehensive capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) study of plasma metabolites. Between-group comparisons of metabolite levels employed the Welch
RESULTS
RESULTS
Of 66 participants, 45 were included in the nocturia group and 21 in the control group. There were no differences in background factors between the two groups. FVC analysis revealed that urine production during night-time, as well as micturition frequency during daytime and night-time were significantly higher in the nocturia group. CE-TOFMS identified eight metabolites whose plasma levels differed between the two groups. Multivariate analysis indicated that increased levels of lauric acid and imidazolelactic acid, as well as decreased levels of thiaproline and glycerol, contribute to the etiology of nocturia in aged men.
CONCLUSIONS
CONCLUSIONS
Our findings suggest that abnormal serum levels of metabolites in several pathways play a role in the pathogenesis of nocturia in aged men.
Identifiants
pubmed: 31205496
doi: 10.1177/1756287219850087
pii: 10.1177_1756287219850087
pmc: PMC6535732
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1756287219850087Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
Conflict of interest statement: Yuka Hashimoto, Hajime Takamatsu, Masayuki Tanahashi, and Masahiro Takeda are employed by Astellas Pharma Inc. The other authors declare that there is no conflict of interest.
Références
Immunopharmacology. 1999 Nov;44(3):281-91
pubmed: 10598885
Anal Chem. 2000 Mar 15;72(6):1236-41
pubmed: 10740865
Anal Chem. 2002 May 15;74(10):2233-9
pubmed: 12038746
Diabetes Educ. 2002 May-Jun;28(3):424-34
pubmed: 12068651
Am J Clin Nutr. 2003 May;77(5):1146-55
pubmed: 12716665
J Proteome Res. 2003 Sep-Oct;2(5):488-94
pubmed: 14582645
Crit Rev Toxicol. 2005 Aug;35(7):609-62
pubmed: 16417045
Urology. 2008 Sep;72(3):556-60
pubmed: 18597823
Urology. 2009 May;73(5):950-7
pubmed: 19394490
Anal Chem. 2009 Aug 1;81(15):6165-74
pubmed: 19522513
J Urol. 2009 Aug;182(2):616-24; discussion 624-5
pubmed: 19539955
Metabolomics. 2010 Mar;6(1):78-95
pubmed: 20300169
BJU Int. 2013 May;111(5):700-16
pubmed: 23360086
Transl Psychiatry. 2014 Apr 08;4:e379
pubmed: 24713860
Neurourol Urodyn. 2014 Apr;33 Suppl 1:S2-5
pubmed: 24729150
Biochimie. 2016 Jun;125:259-66
pubmed: 26542285
Nutr Rev. 2016 Apr;74(4):267-80
pubmed: 26946252
BBA Clin. 2016 Apr 03;5:151-8
pubmed: 27114925
J Urol. 2017 Feb;197(2):423-431
pubmed: 27565397
Sci Rep. 2016 Dec 15;6:39227
pubmed: 27976711
J Urol. 2018 May;199(5):1312-1318
pubmed: 29175111
Curr Urol Rep. 2018 Feb 9;19(1):8
pubmed: 29427214
Ther Adv Urol. 2017 Dec 07;10(2):79-92
pubmed: 29434675
Urol Int. 2018;100(4):445-449
pubmed: 29698965